Loading
Ide-cel tripled progression-free time versus standard regimens in heavily pretreated myeloma, but did not clearly extend life after most control patients crossed over.
KarMMa-3, trial NCT03651128 sponsored by Bristol Myers Squibb and 2seventy and published in the New England Journal of Medicine in 2023, showed that idecabtagene vicleucel tripled progression-free time versus standard regimens in triple-class-exposed myeloma after two to four prior lines, but did not clearly extend life after most control patients crossed over. It randomised 386 patients, met its primary progression-free survival endpoint with a much higher response rate, while unadjusted overall survival was no different and crossover-adjusted analyses favoured ide-cel, leading to approval after two lines in April 2024. OnCo links it to multiple myeloma, idecabtagene vicleucel, Nikhil C. Munshi and the KarMMa-3 paper. Whether ide-cel's smaller effect than cilta-cel in CARTITUDE-4 reflects the product or the population is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Relapsed or refractory multiple myeloma, CAR-T cell therapy.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Relapsed or refractory multiple myeloma, CAR-T cell therapy.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network.
Shares KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, CAR-T cell therapy, Multiple myeloma.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Relapsed or refractory multiple myeloma, CAR-T cell therapy.
Shares Idecabtagene vicleucel, CAR-T cell therapy, Multiple myeloma.